Research
Hormonal
Long-term results with semaglutide and tirzepatide are approaching the success seen with bariatric surgery.
Practitioners should be aware of the effectiveness of semaglutide and tirzepatide in weight management.
LimitedSupportsmedium confidence
Long-term results with semaglutide and tirzepatide are now approaching the success seen with bariatric surgery.
Why this rating
The claim is based on expert opinion.
Source
Obesity and diabetes: the final frontier
Marc Rendell · Expert Review of Endocrinology & Metabolism · 2023
DOI 10.1080/17446651.2023.2168643
reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →